OncBioMune Pharmaceuticals Establishes Another Revenue Stream; Schedules First Patient with AAT Deficiency for Treatment in Mexico

BATON ROUGE, LA--(Marketwired - June 28, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, a proprietary cancer vaccine technology and commercialization of a portfolio of products internationally, is pleased to announce achieving a significant milestone with the first patient in Mexico suffering from Chronic Obstructive Pulmonary Disease (COPD) and Alpha-1 Antitrypsin (AAT) deficiency identified and scheduled to begin treatment with a leading therapy in approximately two weeks. The name of the AAT therapy is being withheld at this time for competitive reasons.

OncBioMune is utilizing Mexico's "Patient Specific" pathway, the equivalent of "Compassionate Use" in the United States, to facilitate importing the product to begin the patient's therapy immediately. AAT deficiency is a lifelong condition requiring weekly injections, with the cost of some popular insurance-covered therapies in excess of $100,000 annually.

Now that a market has been identified, OncBioMune is working to complete licensing negotiations with the treatment's manufacturer with the goal of adding the product to the Company's portfolio for the Mexican market. While utilizing the Patient Specific pathway initially, the Company will seek to leverage data used in regulatory approvals for the product in other countries, a process which management hopes to expedite through an Orphan Drug designation in Mexico, due to the rarity of the disease and lack of leading treatments.

While known to be inherited and considered one of the most common genetic disorders worldwide, no one is certain as to how many people are afflicted with AAT deficiency. Diagnosis of AAT deficiency typically only occurs post-diagnosis of lung or liver disease. A 2012 study authored by Frederick J. de Serres and Ignacio Blanco spanning nearly 100 countries estimates that 4,049 Mexicans have AAT deficiency. The Company believes an accurate estimate is a challenge due to a problem of infrequent diagnostics, leaving many adults and children unaware they have AAT deficiency and at increased risk for degenerative lung function and other maladies. Further, Mexico has a large population of immigrants from Europe, Spain in particular, where AAT deficiency is far more prevalent.